ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.Biochemical genetics · 2024Pooled it
- Global bibliometric analysis of pleural mesothelioma biomarkers (2002-2024): trends and emerging frontiers.Journal of thoracic disease · 2025Article
- De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.EMBO molecular medicine · 2025Article
- Integrative eQTL and Mendelian randomization analysis reveals key genetic markers in mesothelioma.Respiratory research · 2025Article
- Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma.Cell death & disease · 2025Article
- KRAS signaling in malignant pleural mesothelioma.EMBO molecular medicine · 2022Article
- Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions.Cancers · 2021Article
- Identification of Overexpressed Genes in Malignant Pleural Mesothelioma.International journal of molecular sciences · 2021Article
- Association ofCancers · 2021Article
- Four Immune-Related Genes (FN1, UGCG, CHPF2 and THBS2) as Potential Diagnostic and Prognostic Biomarkers for Carbon Nanotube-Induced Mesothelioma.International journal of general medicine · 2021Article
- COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma.BioMed research international · 2021Article
- Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.Respiratory research · 2020Article
- Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.Turk gogus kalp damar cerrahisi dergisi · 2020Article
- Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.Journal of thoracic disease · 2018Review
- Review
- Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.Oncotarget · 2017Article
- Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
purposeTo develop a standardized approach for molecular diagnostics, we used the gene expression ratio bioinformatic technique to design a molecular signature to diagnose malignant pleural mesothelioma (MPM) from among other potentially confounding diagnoses and differentiate the epithelioid from the sarcomatoid histologic subtype of MPM. In addition, we searched for pathways relevant in MPM in comparison with other related cancers to identify unique molecular features in MPM. EXPERIMENTAL
designWe conducted microarray analysis on 113 specimens including MPMs and a spectrum of tumors and benign tissues comprising the differential diagnosis of MPM. We generated a sequential combination of binary gene expression ratio tests able to discriminate MPM from other thoracic malignancies. We compared this method with other bioinformatic tools and validated this signature in an independent set of 170 samples. Functional enrichment analysis was conducted to identify differentially expressed probes.
resultsA sequential combination of gene expression ratio tests was the best molecular approach to distinguish MPM from all the other samples. Bioinformatic and molecular validations showed that the sequential gene ratio tests were able to identify the MPM samples with high sensitivity and specificity. In addition, the gene ratio technique was able to differentiate the epithelioid from the sarcomatoid type of MPM. Novel genes and pathways specifically activated in MPM were identified.
conclusionsNew clinically relevant molecular tests have been generated using a small number of genes to accurately distinguish MPMs from other thoracic samples, supporting our hypothesis that the gene expression ratio approach could be a useful tool in the differential diagnosis of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.